Lactobacillus rhamnosus GG Protects against non-alcoholic fatty liver disease in mice

PLoS ONE

Volumn 9, Issue 1, 2014, Pages

  Ritze, Yvonne ^a   Bárdos, Gyöngyi ^a   Claus, Anke ^a   Ehrmann, Veronika ^a   Bergheim, Ina ^a,b   Schwiertz, Andreas ^c   Bischoff, Stephan C ^a  

^a UNIVERSITY OF HOHENHEIM   (Germany)

^b FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

^c MVZ Institute of Microecology   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; DRINKING WATER; FRUCTOSE; I KAPPA B; INTERLEUKIN 1BETA; INTERLEUKIN 8 RECEPTOR; MESSENGER RNA; PROBIOTIC AGENT; TIGHT JUNCTION PROTEIN; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BACTERIAL STRAIN; CARBOHYDRATE DIET; COLONY FORMING UNIT; CONTROLLED STUDY; FEMALE; HEPATITIS; HUMAN; HUMAN CELL; IL 1BETA GENE; IL 8R GENE; INTESTINE FLORA; INTESTINE MUCOSA PERMEABILITY; LACTOBACILLUS RHAMNOSUS; LIPID METABOLISM; LIPID STORAGE; LIVER PROTECTION; MOUSE; NONALCOHOLIC FATTY LIVER; NONHUMAN; PERMEABILITY BARRIER; TNF ALPHA GENE; TREATMENT OUTCOME;

ALANINE TRANSAMINASE; ANALYSIS OF VARIANCE; ANIMALS; CACO-2 CELLS; DEXTRANS; DNA PRIMERS; FATTY LIVER; FRUCTOSE; HUMANS; IMMUNOHISTOCHEMISTRY; INTESTINE, SMALL; LACTOBACILLUS RHAMNOSUS; MICE; MICE, INBRED C57BL; PERMEABILITY; PROBIOTICS; REAL-TIME POLYMERASE CHAIN REACTION;

EID: 84900346071     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0080169     Document Type: Article

References (50)

1. Abu-Shanab A, Quigley EM (2010) The role of the gut microbiota in nonalcoholic fatty liver disease. Nat Rev Gastroenterol Hepatol 7: 691-701.
2. Henao-Mejia J, Elinav E, Jin C, Hao L, Mehal WZ, et al. (2012) Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity. Nature 482: 179-185.
3. Le Roy T, Llopis M, Lepage P, Bruneau A, Rabot S, et al. (2012) Intestinal microbiota determines development of non-alcoholic fatty liver disease in mice. Gut.
4. Greenblum S, Turnbaugh PJ, Borenstein E (2012) Metagenomic systems biology of the human gut microbiome reveals topological shifts associated with obesity and inflammatory bowel disease. Proc Natl Acad Sci U S A 109: 594-599.
5. Dukowicz AC, Lacy BE, Levine GM (2007) Small intestinal bacterial overgrowth: a comprehensive review. Gastroenterol Hepatol (N Y) 3: 112-122. (Pubitemid 46712476)
6. Wood NJ (2012) Microbiota: Dysbiosis driven by inflammasome deficiency exacerbates hepatic steatosis and governs rate of NAFLD progression. Nat Rev Gastroenterol Hepatol 9: 123.
7. Solga SF, Diehl AM (2004) Gut flora-based therapy in liver disease? The liver cares about the gut. Hepatology 39: 1197-1200. (Pubitemid 38569039)
8. Machado MV, Cortez-Pinto H (2012) Gut microbiota and nonalcoholic fatty liver disease. Ann Hepatol 11: 440-449.
9. Browning JD, Szczepaniak LS, Dobbins R, Nuremberg P, Horton JD, et al. (2004) Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology 40: 1387-1395. (Pubitemid 39657013)
10. Cortez-Pinto H, de Moura MC, Day CP (2006) Non-alcoholic steatohepatitis: from cell biology to clinical practice. J Hepatol 44: 197-208. (Pubitemid 41772535)
11. Angulo P (2002) Nonalcoholic fatty liver disease. N Engl J Med 346: 1221-1231.
12. Park SK, Seo MH, Shin HC, Ryoo JH (2012) The clinical availability of non-alcoholic fatty liver disease as an early predictor of type 2 diabetes mellitus in korean men: 5-years' prospective cohort study. Hepatology.
13. Sheth SG, Gordon FD, Chopra S (1997) Nonalcoholic steatohepatitis. Ann Intern Med 126: 137-145. (Pubitemid 27058588)
14. Lim JS, Mietus-Snyder M, Valente A, Schwarz JM, Lustig RH (2010) The role of fructose in the pathogenesis of NAFLD and the metabolic syndrome. Nat Rev Gastroenterol Hepatol 7: 251-264.
15. Turnbaugh PJ, Ley RE, Mahowald MA, Magrini V, Mardis ER, et al. (2006) An obesity-associated gut microbiome with increased capacity for energy harvest. Nature 444: 1027-1031. (Pubitemid 46018515)
16. Ley RE, Turnbaugh PJ, Klein S, Gordon JI (2006) Microbial ecology: human gut microbes associated with obesity. Nature 444: 1022-1023. (Pubitemid 46018512)
17. Schwiertz A, Taras D, Schafer K, Beijer S, Bos NA, et al. (2010) Microbiota and SCFA in lean and overweight healthy subjects. Obesity (Silver Spring) 18: 190-195.
18. Spruss A, Bergheim I (2009) Dietary fructose and intestinal barrier: potential risk factor in the pathogenesis of nonalcoholic fatty liver disease. J Nutr Biochem 20: 657-662.
19. Cani PD, Bibiloni R, Knauf C, Waget A, Neyrinck AM, et al. (2008) Changes in gut microbiota control metabolic endotoxemia-induced inflammation in high-fat diet-induced obesity and diabetes in mice. Diabetes 57: 1470-1481.
20. Haub S, Kanuri G, Volynets V, Brune T, Bischoff SC, et al. (2010) Serotonin reuptake transporter (SERT) plays a critical role in the onset of fructose-induced hepatic steatosis in mice. Am J Physiol Gastrointest Liver Physiol 298: G335-344.
21. Vieira LQ, dos Santos LM, Neumann E, da Silva AP, Moura LN, et al. (2008) Probiotics protect mice against experimental infections. J Clin Gastroenterol 42 Suppl 3 Pt 2: S168-169.
22. Cani PD, Delzenne NM (2009) The role of the gut microbiota in energy metabolism and metabolic disease. Curr Pharm Des 15: 1546-1558.
23. Nanji AA, Khettry U, Sadrzadeh SM (1994) Lactobacillus feeding reduces endotoxemia and severity of experimental alcoholic liver (disease). Proc Soc Exp Biol Med 205: 243-247. (Pubitemid 24108319)
24. Lebeer S, Vanderleyden J, De Keersmaecker SC (2008) Genes and molecules of lactobacilli supporting probiotic action. Microbiol Mol Biol Rev 72: 728-764, Table of Contents.
25. Xu RY, Wan YP, Fang QY, Lu W, Cai W (2012) Supplementation with probiotics modifies gut flora and attenuates liver fat accumulation in rat nonalcoholic fatty liver disease model. J Clin Biochem Nutr 50: 72-77.
26. Donato KA, Gareau MG, Wang YJ, Sherman PM (2010) Lactobacillus rhamnosus GG attenuates interferon-{gamma} and tumour necrosis factor-alpha-induced barrier dysfunction and pro-inflammatory signalling. Microbiology 156: 3288-3297.
27. Lee SK, Yang KM, Cheon JH, Kim TI, Kim WH (2012) [Anti-inflammatory mechanism of Lactobacillus rhamnosus GG in lipopolysaccharide- stimulated HT-29 cell]. Korean J Gastroenterol 60: 86-93.
28. Johnson-Henry KC, Donato KA, Shen-Tu G, Gordanpour M, Sherman PM (2008) Lactobacillus rhamnosus strain GG prevents enterohemorrhagic Escherichia coli O157:H7-induced changes in epithelial barrier function. Infect Immun 76: 1340-1348. (Pubitemid 351561979)
29. Seth A, Yan F, Polk DB, Rao RK (2008) Probiotics ameliorate the hydrogen peroxide-induced epithelial barrier disruption by a PKC- and MAP kinase-dependent mechanism. Am J Physiol Gastrointest Liver Physiol 294: G1060-1069. (Pubitemid 351520059)
30. Spiller R (2008) Review article: probiotics and prebiotics in irritable bowel syndrome. Aliment Pharmacol Ther 28: 385-396.
31. Bergheim I, Weber S, Vos M, Kramer S, Volynets V, et al. (2008) Antibiotics protect against fructose-induced hepatic lipid accumulation in mice: role of endotoxin. J Hepatol 48: 983-992.
32. Ciorba MA, Riehl TE, Rao MS, Moon C, Ee X, et al. (2012) Lactobacillus probiotic protects intestinal epithelium from radiation injury in a TLR-2/cyclo-oxygenase-2-dependent manner. Gut 61: 829-838.
33. Bacchetti De Gregoris T, Aldred N, Clare AS, Burgess JG (2011) Improvement of phylum- and class-specific primers for real-time PCR quantification of bacterial taxa. J Microbiol Methods 86: 351-356.
34. Schwiertz A, Jacobi M, Frick JS, Richter M, Rusch K, et al. (2010) Microbiota in pediatric inflammatory bowel disease. J Pediatr 157: 240-244 e241
35. Brandt K, Alatossava T (2003) Specific identification of certain probiotic Lactobacillus rhamnosus strains with PCR primers based on phage-related sequences. Int J Food Microbiol 84: 189-196. (Pubitemid 36627397)
36. Lambert D, O'Neill CA, Padfield PJ (2007) Methyl-beta-cyclodextrin increases permeability of Caco-2 cell monolayers by displacing specific claudins from cholesterol rich domains associated with tight junctions. Cell Physiol Biochem 20: 495-506. (Pubitemid 47340610)
37. Ellwood KC, Chatzidakis C, Failla ML (1993) Fructose utilization by the human intestinal epithelial cell line, Caco-2. Proc Soc Exp Biol Med 202: 440-446. (Pubitemid 23097835)
38. Iizuka K (2013) Recent progress on the role of ChREBP in glucose and lipid metabolism. Endocr J 60: 543-555.
39. Zhang L, Li N, des Robert C, Fang M, Liboni K, et al. (2006) Lactobacillus rhamnosus GG decreases lipopolysaccharide-induced systemic inflammation in a gastrostomy-fed infant rat model. J Pediatr Gastroenterol Nutr 42: 545-552. (Pubitemid 43804735)
40. Li N, Russell WM, Douglas-escobar M, Hauser N, Lopez M, et al. (2009) Live and heat-killed Lactobacillus rhamnosus GG: effects on proinflammatory and anti-inflammatory cytokines/chemokines in gastrostomy-fed infant rats. Pediatr Res 66: 203-207.
41. Haub S, Ritze Y, Ladel I, Saum K, Hubert A, et al. (2011) Serotonin receptor type 3 antagonists improve obesity-associated fatty liver disease in mice. J Pharmacol Exp Ther 339: 790-798.
42. Ji YS, Kim HN, Park HJ, Lee JE, Yeo SY, et al. (2012) Modulation of the murine microbiome with a concomitant anti-obesity effect by Lactobacillus rhamnosus GG and Lactobacillus sakei NR28. Benef Microbes 3: 13-22.
43. Yan F, Cao H, Cover TL, Whitehead R, Washington MK, et al. (2007) Soluble proteins produced by probiotic bacteria regulate intestinal epithelial cell survival and growth. Gastroenterology 132: 562-575. (Pubitemid 46274659)
44. Wang Y, Liu Y, Sidhu A, Ma Z, McClain CJ, et al. (2012) Lactobacillus rahmnosus GG culture supernatant ameliorates acute alcohol-induced intestinal permeability and liver injury. Am J Physiol Gastrointest Liver Physiol 303: G32-41.
45. Gratz SW, Mykkanen H, El-Nezami HS (2010) Probiotics and gut health: a special focus on liver diseases. World J Gastroenterol 16: 403-410.
46. Peng L, Li ZR, Green RS, Holzman IR, Lin J (2009) Butyrate enhances the intestinal barrier by facilitating tight junction assembly via activation of AMP-activated protein kinase in Caco-2 cell monolayers. J Nutr 139: 1619-1625.
47. Wagnerberger S, Spruss A, Kanuri G, Stahl C, Schroder M, et al. (2012) Lactobaccilus casei Shirota protects from fructose-induced liver steatosis: A mouse model. J Nutr Biochem.
48. Liu Q, Duan ZP, Ha DK, Bengmark S, Kurtovic J, et al. (2004) Synbiotic modulation of gut flora: effect on minimal hepatic encephalopathy in patients with cirrhosis. Hepatology 39: 1441-1449. (Pubitemid 38569067)
49. Weaver LT, Laker MF, Nelson R (1984) Intestinal permeability in the newborn. Arch Dis Child 59: 236-241. (Pubitemid 14160504)
50. Li Z, Yang S, Lin H, Huang J, Watkins PA, et al. (2003) Probiotics and antibodies to TNF inhibit inflammatory activity and improve nonalcoholic fatty liver disease. Hepatology 37: 343-350. (Pubitemid 36152533)